VistaGen Therapeutics is a California-based biotechnology company that specializes in the application of human pluripotent stem cell (hPSC) technology for drug rescue, including predictive toxicology and drug metabolism screening. The company’s hPSC technology platform, Human Clinical Trials in a Test Tube™, enables accessibility to the heart and liver safety profile of drug rescue variants and other new drug candidates with greater speed and precision than conventional nonclinical testing and technologies used in drug development. Harnessing this technology’s unique power, VistaGen Therapeutics enables “drug rescue” of once-promising-but-now-backshelved drug candidates that have been discontinued by biotechnology or pharmaceutical companies prior to market approval due to unexpected heart or liver safety concerns.
Recently, the company made an appearance at Noble Financial Capital Markets’ 9th Annual Equity Conference. The conference took place Tuesday, January 22, 2013 and Wednesday, January 23, 2013 at the Seminole Hard Rock Hotel in Hollywood, Florida. There, some 100 publicly held companies’ corporate representatives showcased their companies’ profiles, business strategies, and outlooks. Investment portfolio managers and equity analysts were on hand to analyze the representatives’ presentations, ask questions, and get a good all-around sense of how each business offers growth potential.
Having touched upon his executive experience, he then said that the company is “applying stem cell technology in ways [he] has not seen possible in the last couple of decades in this space.” According to a Forbes article from February 2012, the sunk cost of drug development is huge, as the “average drug developed by a major pharmaceutical company costs at least $4 billion.” Likewise, the failure of drug development was noted to be staggering and largely attributable to heart or liver toxicity, with over 50% of drug development efforts failing due to these medical concerns.
Mr. Singh touched upon the efficacy of Human Clinical Trials in a Test Tube in combating these sunk cost risks, as the hPSC technology platform identifies failure potential early in a drug’s development process before too many cost have been paid. In short, the technology lets pharmaceutical companies “bring human biology to the forefront of drug development”, thereby letting them “change the game early” in their drug development stages.
For more information about VistaGen Therapeutics and its technologies, visit: http://www.vistagen.com
Let us hear your thoughts below:
